[Pharmacological action on the thrombocyte link in hemostasis in the treatment of ischemic heart disease].
The expediency of using agents inhibiting the functional property of blood platelets for the treatment and prevention of thrombus formation in the system of arteries is substantiated theoretically and by the findings of experimental and clinical study. Data are cited on the clinical use of acetylsalicylic acid, dipyridamole, clofibrat, and also of such preparations as pyridinol carbamate, nonachlasine, pentoxyphylline, cetedil, heparin, streptokinase and anti-vitamins K for the treatment of patients with ischemic heart disease. The correlations of the clinical effect and the influence of these drugs on various aspects of the functional blood platelet activity is analysed.